The switch (called Haps59) consisted of a fusion between a yeast cytosine deaminase (an enzyme that can activate a prodrug) and the CH1 domain of the human p300 protein, a domain that can bind to the cancer marker HIF-1α. The gene discussed is HIF1A; the disease is cancer.